<DOC>
	<DOCNO>NCT02332512</DOCNO>
	<brief_summary>Apatinib new kind selective Vascular Endothelial Growth Factor Receptor 2 ( VEGFR-2 ) tyrosine kinase inhibitor ( TKI ) . The investigator finish preclinical , phase I phase II clinical study find promising anti-tumor activity tolerable toxicity . A disease-control rate 61.1 % mPFS 4.7 month show apatinib phase II study patient NSCLC . The study aim compare efficacy safety apatinib placebo advance non-squamous non-small cell lung cancer patient .</brief_summary>
	<brief_title>Study Apatinib 3rd/4th Line Treatment Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor ( EGFR )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>1 . Subjects &gt; /= 18 year &lt; /=70 year age time Informed Consent . 2 . Advanced relapse refractory predominantly NSCLC document wildtype EGFR . 3 . At least one measurable lesion accord RECIST 1.1 . 4 . Failure second line chemotherapy . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . 6 . Patients must recover AEs prior treatment randamization . 7 . Adequate bone marrow , liver renal function assess follow laboratory test conduct within 1 week randomization . HB ≥ 90g/L ; ANC≥1.5×10E+9/L ; PLT≥80×10E+9/L ; ALT AST &lt; 2.5×ULN ; TBIL ≤1.25×ULN ; Cr ≤1.25×ULN ; CL &gt; 45 ml/min . 8 . Life expectancy least three month . 9 . Written inform consent willingness ability comply aspects protocol . 1 . Presence type smallcell , squamouscell , adenosquamouscell lung cancer . 2 . Pregnant breastfeed woman . 3 . Suffered grade II myocardial ischemia myocardial infarction , uncontrolled arrhythmia ( include QT interval male ≥ 450 m , female≥ 470 m ) .Severe uncontrolled systemic disease clinically significant hypertension ( systolic pressure &gt; /= 140 mm Hg and/or diastolic pressure &gt; /= 90 mm Hg ) , Grade IIIIV cardiac insufficiency , accord NYHA criterion echocardiography check : LVEF &lt; 50 % . 4 . Factors affect oral administration ( inability swallow tablet , GI tract resection , chronic bacillary diarrhea intestinal obstruction ) . 5 . Coagulation disfunction , hemorrhagic tendency receive anticoagulant therapy &gt; /= CTCAE 2 pneumorrhagia &gt; /= CTCAE 3 hemorrhage organ within 4 week . 6 . Bone fracture wound cure . 7 . Arterial thrombus phlebothrombosis within 12 month take anticoagulant agent . 8 . Mental disease psychotropic substance abuse . 9 . Previous treatment trial agent within 4 week 10 . Previous treatment VEGFR , platelet derive growth factor receptor ( PDGFR ) TKIs . 11 . Proteinuria ≥ ( ++ ) 24 hour total urine protein &gt; 1.0 g. 12 . Other coexist malignant disease ( except basalcell carcinoma carcinoma situ uterine cervix ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non-squamous non-small cell lung cancer</keyword>
	<keyword>Wild-type EGFR</keyword>
	<keyword>3rd/4th line treatment</keyword>
	<keyword>apatinib</keyword>
</DOC>